FOLD News and Press, Amicus Therapeutics Inc. From 10/25/18

NEW YORK, Oct. 25, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of PennyMac Mortgage Investment Trust (NYSE:PMT), Amicus Therapeutics, In...

NEW YORK, NY / ACCESSWIRE / October 15, 2018 / U.S. markets bounced on Friday, erasing some of the losses for the week, as the third quarter earnings season kicked off. The Dow Jones Industrial Average jumped 1.15 percent to close at 25,339.99, while the S&P 500 Index increased 1.42 perc...

Management and External Thought Leaders to Highlight Robust Portfolio of Novel Therapies for Rare Metabolic Diseases Webcast Scheduled from 8:30am – 12:30pm E.T. CRANBURY, N.J., Oct. 11, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics, Inc. (NASDAQ: FOLD), a global biotechnology com...

InsiderInsights' Daily Round-Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signi...

Amicus Therapeutics (NASDAQ: FOLD )  announces a major collaboration with the Gene Therapy Program in the Perelman School of Medicine at the University of Pennsylvania to pursue R&D of novel gene therapies for Pompe disease, Fabry disease, CDKL5 deficiency and one additional undisc...

Collaboration Focuses on Four Genetic Disorders: Pompe, Fabry, CDKL5 and One Additional Undisclosed Rare Metabolic Disorder Combines Amicus Expertise in Protein Engineering with Penn’s AAV Vector Technology, Manufacturing and Immunology Capabilities Leverages The Wilson Lab ...

Amicus Therapeutics (NASDAQ: FOLD ) announces positive results from a global Phase 1/2 clinical study (ATB200-02) to investigate AT-GAA in patients with Pompe disease. More news on: Amicus Therapeutics, Inc., Healthcare stocks news, Read more ...

Consistent and Durable Responses Across Key Measures of Safety, Functional Outcomes and Biomarkers Continue Out to Month 18 for both ERT-Naïve and ERT-Switch Patients Very Low Rate (<1%) of Infusion Associated Reactions Maintained After ~900 Infusions CRANBURY, N.J...

CRANBURY, N.J., Oct. 02, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), today announced that an oral presentation and a poster highlighting its development program AT-GAA for Pompe disease will be included at the 23rd International Congress of the World Muscle Society , to be h...

Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Friday, September 28 . Bullish Calls Groupon (GRPN): Cramer had recommended a buy at $4, and it has come down since. He is still behind the stock, as the company has a strong balance sheet and is doing we...